This cohort consisted predominately of stage III and IV melanoma patients, with 74.4% (n = 64/86) of these seropositive for ROPN1A/B, and 62.8% (n = 54/86) seropositive for NY-ESO-1. This evidence concerns the gene ROPN1 and melanoma.